These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 28147262)

  • 1. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
    Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
    Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
    J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
    Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
    BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
    de la Rubia Navarro M; Ivorra Cortés JR; Grau García E; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(7):344-346. PubMed ID: 35811138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.